Anavex life sciences reports data review by the independent data safety monitoring board for its phase 2b/3 clinical trial of anavex®2-73 in patients with alzheimer's disease

New york, march 31, 2021 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced that the independent data safety monitoring board (dsmb) for the company's phase 2b/3 alzheimer's disease study of its investigational compound anavex®2-73 (blarcamesine) has completed its recent pre-planned review of the preliminary phase 2b/3 study data.
AVXL Ratings Summary
AVXL Quant Ranking